Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bayer
Femme et Homme Max 99 ans
Bayer Health Care AG
MAJ Il y a 4 ans
Safety of Gadovist® in Renally Impaired Patients
The primary objective is to assess the magnitude of potential risk with the administration of Gadovist in patients with moderate to severe renal impairment for the development of NSF, based on diagnos...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer AG
MAJ Il y a 4 ans
A study investigating the efficacy and safety of anetumab ravtansine as 2nd line treatment for malignant pleural mesothelioma
Test the superiority of anetumab ravtansine monotherapy over vinorelbine in progression-free survival (PFS)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Controlled, Double-Blind, Randomized, Dose-ranging Study of once-daily regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement-ODIXa-OD.HIP Study
The objective of this dose-ranging trial is to assess the efficacy and safety of BAY 59-7939 5 mg – 40 mg once daily dosing in prevention of VTE in men and in postmenopausal women aged 18 years or ab...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bayer AG
MAJ Il y a 4 ans
Study of radium-223 dichloride versus placebo and hormonal treatment as background therapy in subjects with bone predominant HER2 negative hormone receptor positive metastatic breast cancer
To assess the efficacy and safety of radium-223 dichloride in subjects with HER2 negative, hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background thera...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer plc
MAJ Il y a 4 ans
select-d: Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism
http://www.cancerresearchuk.org/cancer-help/trials/a-study-comparing-blood-thinning-injection-with-blood-thinning-tablet-for-people-with-cancer-who-have-blood-clot-select-d
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolism
The primary objective of this study is to investigate pharmacokinetics and pharmacodynamics of single oral doses of rivaroxaban in paediatric subjects in order to obtain weight adjusted doses with equ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer HealthCare Pharmaceuticals INC
MAJ Il y a 4 ans
Trial to evaluate the effect of two treatment regimens for adults with severe hemophilia A
To evaluate the effects of secondary prophylaxis on bleeding frequency (number of all bleeds per year) compared to episodic treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer Healthcare AG, D-51368 Leverkusen, Germany
MAJ Il y a 4 ans
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients with Stage IIIb with effusion and stage IV Non-Small Cell Lung Cancer (NSCLC)
The objectives of this phase III study are to compare the efficacy and safety of sorafenib in combination with gemcitabine and cisplatin versus placebo with gemcitabine and cisplatin for first-line tr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Bayer AG
MAJ Il y a 4 ans
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine Fibroids
The primary objective of this study is to assess the efficacy of vilaprisan in subjects with uterine fibroids compared to ulipristal.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 4 ans
Proof of concept study to investigate the impact of BAY 58-2667 given intravenously in patients with acute decompensated chronic congestive heart failure
The primary objective of part A is to investigate the hemodynamic and subjective effects on dyspnoea and well-being of 3 doses of BAY 58-2667 given intravenously over 2 hours per dose step in a dose e...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
14
15
16
17
18
19
20
21
22
23
Suivant